GlaxoSmithKline PLC banner

GlaxoSmithKline PLC
NYSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
NYSE:GSK
Watchlist
Price: 51.61 USD -1.34% Market Closed
Market Cap: $105.2B

P/E

13.6
Current
11%
Cheaper
vs 3-y average of 15.3

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
13.6
=
Market Cap
$87.4B
/
Net Income
£5.7B

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
13.6
=
Market Cap
$87.4B
/
Net Income
£5.7B

Valuation Scenarios

GlaxoSmithKline PLC is trading below its 3-year average

If P/E returns to its 3-Year Average (15.3), the stock would be worth $58.21 (13% upside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-98%
Maximum Upside
+13%
Average Downside
47%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 13.6 $51.61
0%
3-Year Average 15.3 $58.21
+13%
5-Year Average 13.1 $49.71
-4%
Industry Average 0.3 $1.12
-98%
Country Average 0.2 $0.79
-98%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
$87.4B
/
Jan 2026
£5.7B
=
13.6
Current
$87.4B
/
Dec 2026
£7.5B
=
11.6
Forward
$87.4B
/
Dec 2027
£8.2B
=
10.7
Forward
$87.4B
/
Dec 2028
£8.5B
=
10.3
Forward
$87.4B
/
Dec 2029
£9.2B
=
9.5
Forward
$87.4B
/
Dec 2030
£8.9B
=
9.9
Forward
$87.4B
/
Dec 2031
£8.7B
=
10
Forward
$87.4B
/
Dec 2032
£8.1B
=
10.8
Forward
$87.4B
/
Dec 2033
£7.7B
=
11.4
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Peer Comparison

All Countries
Close

Market Distribution

Higher than 76% of companies in United Kingdom
Percentile
76th
Based on 2 117 companies
76th percentile
0.4
Low
0 — 0.1
Typical Range
0.1 — 0.3
High
0.3 —
Distribution Statistics
United Kingdom
Min 0
30th Percentile 0.1
Median 0.2
70th Percentile 0.3
Max 828.3

GlaxoSmithKline PLC
Glance View

Once upon a time, in the bustling world of pharmaceuticals, GlaxoSmithKline PLC established itself as a formidable player. Born out of mergers and continuous evolution, GSK, as it is commonly known, carved its place in the competitive landscape through strategic research and pioneering innovations. The company operates at the intersection of pharmaceuticals, vaccines, and consumer healthcare, leveraging its breadth to tackle some of the world's most pressing health challenges. From its bustling laboratories to clinical trials, and finally to market, GSK is driven by a mission to improve the quality of human life. Its intricate network of research facilities and production plants stretch across the globe, working tirelessly to develop essential medications and vaccines that span a variety of therapeutic areas including respiratory, HIV, oncology, and immunology. GSK’s revenue streams flow from a well-diversified portfolio. The pharmaceutical division, representing the lion’s share, innovates and produces transformative medicines. Its vaccines division stands strong, leading with essential inoculations that prevent childhood and adult diseases, while the consumer healthcare segment provides everyday wellness products ranging from pain relief to vitamins and skincare. This triad not only underscores GSK’s dynamic adaptability to market needs but also highlights its resilience in weathering the cyclical nature of the healthcare industry. With a keen eye on long-term value and sustained investment in research and development, GSK continues to create a bridge between scientific advancements and societal well-being, defining its role as both a scientific leader and a profit-driven enterprise.

GSK Intrinsic Value
52.48 USD
Undervaluation 2%
Intrinsic Value
Price $51.61
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett